increasing competition in pharmaceuticals act this bill amends the federal food , drug , and cosmetic act to revise provisions regarding review and approval of generic drug applications or supplements to generic drug applications for drugs : ( 1 ) for which there is a shortage , or ( 2 ) that have not been recently introduced to the market by more than one manufacturer and for which tentative approval has not been granted to more than two applications .
the food and drug administration ( fda ) must prioritize the review of such submissions and act on them within 150 days .
user fees are waived for such an application unless the drug is under patent .
the fda may expedite the inspection of a facility proposed to manufacture such a drug .
the fda must award a transferrable generic drug priority review voucher to the sponsor of such an application upon approval .
a voucher may be used to have the fda review and take action upon a generic drug application within 150 days of submission .
the fda may revoke a voucher awarded for a drug that is not marketed within one year of approval .
this voucher program is terminated at the end of fy2022 .
the fda must periodically report on generic drug applications filed before fy2016 that are still pending .
for a new drug application to be eligible for a priority review voucher as a tropical disease product application , the application must include new , essential clinical investigations .
the government accountability office must study the fda 's program for drug risk evaluation and mitigation strategies .